Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Type
Article
Change log
Authors
Zhao, Tian X
Sriranjan, Rouchelle S
Tuong, Zewen Kelvin
Sage, Andrew P
Abstract
Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease This phase 1b/2a, randomized, double-blind, placebo-controlled, dose-escalation trial tested low-dose subcutaneous aldesleukin (recombinant IL-2) in patients with ischemic heart disease. Low-dose IL-2 expanded Tregs, without adverse events of major concern. Single-cell RNA-sequencing of circulating immune cells was used to provide mechanistic assessment of the treatment's effects.
Description
Keywords
Journal Title
NEJM Evid
Conference Name
Journal ISSN
2766-5526
2766-5526
2766-5526
Volume Title
Publisher
Massachusetts Medical Society
Publisher DOI
Sponsorship
British Heart Foundation (CH/10/001/27642)
Medical Research Council (MR/N028015/1)
Engineering and Physical Sciences Research Council (EP/N014588/1)
EPSRC (EP/T017961/1)
British Heart Foundation (CH/10/001/27642)
Medical Research Council (MR/S035842/1)
Department of Health (via National Institute for Health Research (NIHR)) (RP-2017-08-ST2-002)
Medical Research Council (MR/N028015/1)
Engineering and Physical Sciences Research Council (EP/N014588/1)
EPSRC (EP/T017961/1)
British Heart Foundation (CH/10/001/27642)
Medical Research Council (MR/S035842/1)
Department of Health (via National Institute for Health Research (NIHR)) (RP-2017-08-ST2-002)